

West Virginia Pharmacy Services



Drug Utilization Review (DUR)

3rd Quarter 2015

Prepared by:  MOLINA
Medicaid Solutions

**West Virginia Department of Health and Human Resources
Bureau for Medical Services**

**DUR QUARTERLY OVERALL SUMMARY REPORT
FOR THE PERIOD 07/01/2015 THROUGH 09/30/2015**

Categories	3rd Qtr 2015	3rd Qtr 2014	% Change
Total Paid Amount	\$92,038,681.08	\$102,058,151.05	-9.82
Eligible Members	261,950	243,323	7.66
Utilizing Eligibles	148,596	156,114	-4.82
Total # Prescriptions	1,409,330	1,843,920	-23.57
Cost per Utilizing Member	\$619.39	\$653.74	-5.25
Average # Prescriptions per Utilizer	9.00	11.00	-18.18
Average Cost per Prescription	\$65.31	\$55.35	17.99
# Generic Prescriptions	1,220,935	1,590,515	-23.24
% Generic Prescriptions	86.00	86.00	0.00
Total Cost - Generics	\$23,041,864.21	\$27,529,233.22	-16.30
Average Generic Prescription Cost	\$18.87	\$17.31	9.04
Average Days Supply - Generics	25.00	25.00	0.00
# Brand Prescriptions	188,395	253,405	-25.65
% Brand Prescriptions	13.00	13.00	0.00
Total Cost - Brand	\$68,996,816.87	\$74,528,917.83	-7.42
Average Brand Prescription Cost	\$366.23	\$294.11	24.52
Average Days Supply - Brand	25.00	26.00	-3.85
Rebates Collected	\$75,761,596.93	\$60,045,544.85	26.17

Drug Utilization Review Board Meeting

Disclaimer: This report is for trending purposes only and is not intended to match other financial reports.


Top 25 Therapeutic Classes By Prescription Count

Reporting Months (3rd Quarter): 07/01/2015 - 09/30/2015

Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONVULSANTS	H4B	104,313	7.30	\$5,581,170.81
2	ANALGESICS, NARCOTICS	H3A	73,544	5.10	\$2,172,926.46
3	PROTON-PUMP INHIBITORS	D4J	64,112	4.50	\$2,208,448.46
4	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	54,552	3.80	\$453,706.98
5	ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	M4D	52,141	3.60	\$1,538,000.91
6	NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE	S2B	47,366	3.30	\$489,131.09
7	ANTI-ANXIETY DRUGS	H2F	45,931	3.20	\$373,791.71
8	ANTIHYPERTENSIVES, ACE INHIBITORS	A4D	37,642	2.60	\$251,460.75
9	BETA-ADRENERGIC BLOCKING AGENTS	J7C	37,190	2.60	\$563,458.36
10	ANTIHISTAMINES - 2ND GENERATION	Z2Q	36,421	2.50	\$259,515.61
11	BETA-ADRENERGIC AGENTS	J5D	33,114	2.30	\$1,688,423.14
12	SKELETAL MUSCLE RELAXANTS	H6H	29,348	2.10	\$393,671.00
13	THYROID HORMONES	P3A	28,190	2.00	\$408,606.42
14	ANTIpsychOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	H7T	26,660	1.90	\$3,439,177.11
15	VITAMIN D PREPARATIONS	C6D	25,396	1.80	\$168,745.21
16	ANTIHYPERGLYCEMIC, BIGUANIDE TYPE	C4L	23,854	1.70	\$285,209.37
17	ANTIHISTAMINES - 1ST GENERATION	Z2P	21,506	1.50	\$239,153.37
18	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	20,544	1.40	\$667,447.42
19	INSULINS	C4G	19,947	1.40	\$9,686,425.82
20	CALCIUM CHANNEL BLOCKING AGENTS	A9A	19,339	1.40	\$212,626.53
21	HISTAMINE H2-RECEPTOR INHIBITORS	Z2D	18,491	1.30	\$167,749.32
22	LEUKOTRIENE RECEPTOR ANTAGONISTS	Z4B	17,950	1.30	\$416,584.48
23	GLUCOCORTICOIDS	P5A	17,542	1.20	\$373,337.73
24	PENICILLINS	W1A	15,989	1.10	\$233,554.70
25	THIAZIDE AND RELATED DIURETICS	R1F	15,956	1.10	\$118,923.74
Totals:			887,038	62.00	\$32,391,246.50

Top 12 Therapeutic Classes by Prescription Count

Reporting Months (3rd Quarter): 07/01/2015 - 09/30/2015



Amount Paid

ANTICONSULSANTS	\$5,581,170.81
ANALGESICS, NARCOTICS	\$2,172,926.46
PROTON-PUMP INHIBITORS	\$2,208,448.46
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$453,706.98
ANTHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	\$1,538,000.91
NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE	\$489,131.09
ANTI-ANXIETY DRUGS	\$373,791.71
ANTHYPERTENSIVES, ACE INHIBITORS	\$251,460.75
BETA-ADRENERGIC BLOCKING AGENTS	\$563,458.36
ANTIHISTAMINES - 2ND GENERATION	\$259,515.61
BETA-ADRENERGIC AGENTS	\$1,688,423.14
SKELETAL MUSCLE RELAXANTS	\$393,671.00


Top 25 Therapeutic Classes by Amount Paid

Reporting Months (3rd Quarter): 07/01/2015 - 09/30/2015

	Therapeutic Class	Therapeutic Class Code	Amount Paid	% of Total Amount Paid	Prescription Count
1	INSULINS	C4G	\$9,686,425.82	10.50	19,947
2	ANTICONVULSANTS	H4B	\$5,581,170.81	6.10	104,313
3	BETA-ADRENERGIC AND GLUCOCORTICOID COMBINATIONS	J5G	\$4,620,267.51	5.00	15,888
4	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	H7X	\$4,268,180.59	4.60	4,786
5	ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	H7T	\$3,439,177.11	3.70	26,660
6	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$2,551,756.19	2.80	734
7	GENERAL BRONCHODILATOR AGENTS	A1D	\$2,496,209.06	2.70	8,688
8	HEP C VIRUS - NS5B POLYMERASE & NS5A INHIB. COMBO.	W0B	\$2,215,972.84	2.40	91
9	PROTON-PUMP INHIBITORS	D4J	\$2,208,448.46	2.40	64,112
10	ANALGESICS, NARCOTICS	H3A	\$2,172,926.46	2.40	73,544
11	AGENTS TO TREAT MULTIPLE SCLEROSIS	H0E	\$2,088,255.27	2.30	400
12	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	\$1,736,421.19	1.90	11,007
13	NARCOTIC WITHDRAWAL THERAPY AGENTS	H3W	\$1,723,229.07	1.90	14,591
14	BETA-ADRENERGIC AGENTS	J5D	\$1,688,423.14	1.80	33,114
15	ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	M4D	\$1,538,000.91	1.70	52,141
16	ANTIHYPERGLYCEMIC, DPP-4 INHIBITORS	C4J	\$1,383,445.53	1.50	4,321
17	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	H2V	\$1,344,183.64	1.50	8,306
18	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$1,237,204.90	1.30	144
19	LIPOTROPICS	M4E	\$1,151,567.12	1.20	11,977
20	NASAL ANTI-INFLAMMATORY STEROIDS	Q7P	\$1,114,736.54	1.20	15,606
21	BLOOD SUGAR DIAGNOSTICS	M4A	\$962,024.59	1.00	15,301
22	ANTISERA	W7K	\$890,859.42	1.00	209
23	GROWTH HORMONES	P1A	\$720,086.73	0.80	250
24	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	\$667,447.42	0.70	20,544
25	ANTI-ALCOHOLIC PREPARATIONS	C0D	\$640,816.18	0.70	817
Totals:			\$58,127,236.50	63.10	507,491

Top 12 Therapeutic Classes by Amount Paid

Reporting Months (3rd Quarter): 07/01/2015 - 09/30/2015




Prescriptions

INSULINS	19,947
ANTICONVULSANTS	104,313
BETA-ADRENERGIC AND GLUCOCORTICOID COMBINATIONS	15,888
ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	4,786
ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	26,660
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	734
GENERAL BRONCHODILATOR AGENTS	8,688
HEP C VIRUS - NS5B POLYMERASE & NS5A INHIB. COMBO.	91
PROTON-PUMP INHIBITORS	64,112
ANALGESICS, NARCOTICS	73,544
AGENTS TO TREAT MULTIPLE SCLEROSIS	400
ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	11,007

Generic Utilization Summary By Amount Paid

Reporting Months (3rd Quarter): 07/01/2015 - 09/30/2015

Generic Utilization Summary by Amount Paid




	BNG	\$57,035,011	61.9%
	BWG	\$11,969,113	13.0%
	GEN	\$23,203,369	25.2%
Total:		\$92,207,492	100.0%

BNG = Brand With no Generic Available BWG = Brand Dispensed when Generic Available
GEN=Generic

Generic Utilization Summary by Number of Prescriptions

Reporting Months (3rd Quarter): 07/01/2015 - 09/30/2015

Generic Utilization Summary by Number of Prescriptions




	BNG	134,826	9.4%
	BWG	53,657	3.8%
	GEN	1,241,394	86.8%
Total:		1,429,877	100.0%

BNG = Brand With no Generic Available **BWG = Brand Dispensed when Generic Available**
GEN=Generic

Drug Utilization Review Savings

Reporting Months (3rd Quarter) 07/01/2015 - 09/30/2015

DUR SAVINGS



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$263,515.10	2.00
ER	Early Refill	\$8,859,597.02	59.00
HD	High Dose	\$672,094.98	4.00
ID	Ingredient Duplication	\$527,992.17	3.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$83,242.30	1.00
TD	Therapeutic Duplication	\$4,706,011.59	31.00
Totals:		\$15,112,453.15	100.00